Windlas Biotech Limited (WINDLAS) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Windlas Biotech Limited stock ₹559, price ₹977, that is 42.8% below the price, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Windlas Biotech Limited
WINDLAS · NSEFar too expensive (fair value 43% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
60‑month range ₹197.48 – ₹1,155 · fair‑value band ₹273.51 – ₹832.79 · the ₹977.20 price screens above the ₹558.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.
Every Wednesday you see whether Windlas Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India.
Show moreShow less
The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services.
It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules.
In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies.
It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.
Stock analysis
Windlas Biotech Limited (WINDLAS) currently trades at ₹977.20, while our model-based Fair Value estimate is ₹558.96, 43% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹824.62 per share, and 1 of the 26 models we run sit above the ₹977.20 price.
Bear case: the Dividend Discount group reads lowest at ₹70.06, and 25 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹273.51 (bear) to ₹832.79 (bull), the price of ₹977.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Windlas Biotech Limited reported revenue of ₹9.0B in FY2026 versus ₹4.6B in FY2022, a compound +18.2%/yr. Reported net income was ₹665M in FY2026, compounding +14.9%/yr from FY2022.
Key figures
Market cap ₹20.8B (≈ $221M) Micro · P/E ratio 31.3 · P/S ratio 2.21 · EPS (TTM) ₹31.26 · Dividend yield 0.6% · Net margin 7.1% · Return on equity 12.2% · Return on assets (EBIT) 8.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (medium confidence).
What moves the price
The share trades about 15% below its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −43%, WINDLAS screens richer than that median.
Fair Value models
All 26 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
WINDLAS screens overvalued: fair value 43% below the price. Compare with Merck KGaA →
Compare Windlas Biotech Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on equity by industry
- Quality Score by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs WINDLAS |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs WINDLAS |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs WINDLAS |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs WINDLAS |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs WINDLAS |
| Galderma Group GALD | CHF 191.00 | CHF 112.30 | −41% | vs WINDLAS |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs WINDLAS |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs WINDLAS |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs WINDLAS |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs WINDLAS |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Windlas Biotech Limited (WINDLAS) overvalued or undervalued?
What is the fair value of WINDLAS?
What is the quality score of WINDLAS?
What is the price target for Windlas Biotech Limited (WINDLAS)?
What is the Windlas Biotech Limited stock forecast for 2026?
What is the revenue of Windlas Biotech Limited (WINDLAS)?
Does Windlas Biotech Limited pay a dividend?
How much is the dividend of Windlas Biotech Limited (WINDLAS) and when is the ex-dividend date?
What growth is priced into Windlas Biotech Limited (WINDLAS)?
What discount rate (WACC) does the fair value of WINDLAS use?
What is a reverse DCF?
How much growth has Windlas Biotech Limited (WINDLAS) delivered so far?
How fast is the sector of Windlas Biotech Limited (WINDLAS) growing?
What is the free cash flow yield of Windlas Biotech Limited (WINDLAS)?
What is the intrinsic value of Windlas Biotech Limited (WINDLAS)?
Is Windlas Biotech Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of WINDLAS?
How much is Windlas Biotech Limited worth?
What do the bullish and bearish scenarios say about WINDLAS?
What is the P/E ratio of WINDLAS?
How solid is the balance sheet of Windlas Biotech Limited (WINDLAS)?
How far is WINDLAS from its 52-week high?
Which stocks are comparable to Windlas Biotech Limited?
Is Windlas Biotech Limited stock attractive at the current price?
How is the fair value of WINDLAS calculated?
Is it still worth investing in stocks now?
What is the share price of Windlas Biotech Limited (WINDLAS)?
What should I pay attention to with Windlas Biotech Limited right now?
Key figures of Windlas Biotech Limited
How large is the market capitalisation of Windlas Biotech Limited (WINDLAS)?
What is the P/S ratio of Windlas Biotech Limited (WINDLAS)?
What are the earnings per share of Windlas Biotech Limited (WINDLAS)?
What is the dividend yield of Windlas Biotech Limited (WINDLAS)?
What is the net margin of Windlas Biotech Limited (WINDLAS)?
What is the return on equity of Windlas Biotech Limited (WINDLAS)?
What is the EBIT return on assets of Windlas Biotech Limited (WINDLAS)?
What is the operating margin of Windlas Biotech Limited (WINDLAS)?
How fast is revenue growing at Windlas Biotech Limited (WINDLAS)?
How fast are earnings growing at Windlas Biotech Limited (WINDLAS)?
How much net debt does Windlas Biotech Limited (WINDLAS) carry?
Watch Windlas Biotech Limited in the live analysis
One click puts Windlas Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.